The European Parliament heads into a Wednesday vote to reject a European Commission carve-out that would have let cosmetics containing cancer-linked chemicals stay on the EU market, aligning the chamber with national governments that already blocked the proposal last year.

The contested clause sits inside a Commission "omnibus" package that bundles changes to cosmetics rules, fertilizer regulation and chemical labeling (CLP). Within the cosmetics file, the Commission argued that when a substance's hazard is driven mainly by ingestion or inhalation — rather than by skin contact — its use in a cosmetic "does not result in the same level of risk for end-users," since such exposure is usually incidental. Commission staff indirectly cited lipstick as the category example.

Parliament committees rejected the draft earlier this month. The Council of the EU did so in 2025.

What would the Commission's route-specific approach have changed for formulators?

The Commission wanted to relax restrictions on CMR (carcinogenic, mutagenic, reprotoxic) substances used in cosmetics when the proven hazard route differed from how consumers actually apply the product. Critics inside Parliament and consumer groups countered that aggregate, lifelong exposure across lip, face and body products makes route-by-route carve-outs unreliable.

Pelle Moos, senior adviser at the European Consumer Organisation, called the expected Parliament position "a major blow for the Commission's plans to weaken critical consumer safeguards against hazardous chemicals."

For R&D and regulatory teams, the practical signal is straightforward:

• Annexes II, III, IV and VI under Regulation (EC) 1223/2009 stay intact
• No route-specific CMR exemption is being introduced
• Existing CMR entries in the Cosmetics Ingredients database remain enforceable

Who is steering the file in Parliament?

Two lawmakers lead the file: Dimitris Tsiodris (European People's Party) and Piotr Müller (European Conservatives and Reformists group). Both had initially pushed for more compliance runway when new substances are flagged.

Müller said he "would have preferred even bolder regulatory frameworks to truly unleash our business potential and drive innovation." He and Tsiodris ultimately joined the pushback, putting the Parliament on the same side as the Council.

What does the five-year phase-out mean for brand owners and suppliers?

Parliament's draft gives companies up to five years to phase out substances newly classified as carcinogenic, mutagenic or reprotoxic once a CMR classification lands through ECHA. Danish MEP Per Clausen, who steers the omnibus for The Left, attacked the runway itself:

"We are now introducing a phase-out of substances and chemicals that have been declared dangerous and banned. Yet they are being allowed to remain on the market for more than five years after that decision."

For procurement and reformulation leads, the timeline is now the planning window. Any ingredient flagged via the 15th or 16th ATP to the CLP Regulation — or via a downstream RAC opinion — needs substitution work starting immediately, on the assumption of a five-year coexistence ceiling before mandatory reformulation deadlines harden.

What comes next after the plenary vote

The Wednesday vote sends the file into trilogue between Parliament, Council and the Commission. The Commission acts as moderator rather than co-legislator on this dossier, which leans the negotiation toward retaining current safeguards. Industry associations that backed the carve-out — particularly those representing color-cosmetic and lipstick formulators — now face a compressed compliance horizon once a CMR listing drops.

Watchpoints through Q3 2026: any Commission move to relaunch the route-specific approach through delegated acts under CLP Article 4, ECHA's progress on pending CMR dossiers, and whether the Council confirms its 2025 rejection in trilogue or reopens individual substance classes.